HHS' decision "could stagnate research that has the potential to save millions of lives," writes Simon Williams.

Q2 2025 Earnings Call Transcript August 14, 2025 Cellectar Biosciences, Inc. beats earnings expectations. Reported EPS is $-3 ...

August 14, 2025BioLineRx Ltd. misses on earnings expectations. Reported EPS is $-1 EPS, expectations were $-0.35. Operator: ...

GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2's formal safety review, it has advanced into Cohort 3 and ...

Key Points GAAP loss per share of $(0.47) for Q2 2025 was narrower than the $(0.53) analysts had expected, despite an ongoing absence of revenue. Research and development expenses (GAAP) increased 35.

Management reiterated the expectation that Elfabrio royalties will exceed $100 million by 2030, based on a projected 15% to 20% market share of the Fabry disease market.

Over the past 20 years, a class of cancer drugs called CD40 agonist antibodies have shown great promise-and induced great disappointment.

Cash and equivalents (GAAP) totaled $13.1 million as of Q2 2025. These 10 stocks could mint the next wave of millionaires › Traws Pharma (NASDAQ:TRAW), a clinical-stage biopharmaceutical company ...

Operator: Greetings. Welcome to PDS Biotech Second Quarter 2025 Earnings Conference Call. [Operator Instructions] As a ...

A Phase 1 human clinical trial to treat chronic spinal cord injury, the first of its kind in the world, has commenced to test ...

Therapeutic advances have altered the neurodegenerative trajectory and improved clinical outcomes for individuals with spinal muscular atrophy. Current therapies increase concentrations of survival ...

NRG Oncology recently reported the results of the phase II/III NRG-BN007 clinical trial showing that combining ipilimumab and ...